During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead programme, IB-T101, for clear cell renal cell carcinoma (ccRCC). The trial ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

The international AURORAX-0087A (AUR87A) study is assessing whether a GAGome test can accurately detect the return of clear cell renal cell carcinoma (ccRCC) following surgery. This is the most ...

For the study, Dabestani and his colleagues enrolled 134 patients with ccRCC treated at 23 hospitals in the United Kingdom, the European Union, the United States, and Canada. All participants had ...

The first-in-human PET imaging trial of 64 Cu-PD-32766 for patients with clear cell renal cell carcinoma (ccRCC) was conducted at the National Cancer Center Hospital East and promising results ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO ...

– Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – ...

The first-in-human PET imaging trial of 64 Cu-PD-32766 for patients with clear cell renal cell carcinoma (ccRCC) was conducted at the National Cancer Center Hospital East and promising results were ...